Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Cipla
Cipla
Activities:
Ingredients
Drug Delivery
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Finance
Cipla and Kemwell announce joint venture for biosimilars
The venture will leverage the companies’ combined strengths in product development, clinical development, regulatory filings, manufacturing and commercialisation
Ingredients
Cipla signs COVID-19 licensing agreement with Gilead Sciences
Indian Cipla will be permitted to manufacture US-based Gilead’s API and finished product of Remdesivir and market it in 127 countries including India and South Africa under its own brand name
Research & Development
Indian Cipla funnels $1 million into facility in Minsk
The facility will be used to localise the production of innovative solid medicines in Belarus
Finance
Cipla to step up efforts in US market
Competition heating up, with the US Food and Drug Association approving rival drugs, which could eat away at Cipla's market share in the generic business.
Regulatory
Indian pricing authority to address overcharging by pharma companies
NPPA has decided to chase drug majors for defaulting on penalties that have been imposed for overcharging consumers for medicines
Finance
Cipla to acquire two US generics companies for $550m
Acquisition of InvaGen gives Cipla scale in the US generics market with a strong manufacturing and R&D base, access to a broad product portfolio and a strong customer base
Regulatory
Boehringer Ingelheim suffers Spiriva patent blow in India
Indian patent office has revoked a patent granted for tiotropium bromide monohydrate under the Spiriva brand, paving the way for Cipla to continue selling its generic version in the Indian market
Subscribe now